Oct 2026· Hematology/Oncology Clinics of North America· Vol 40 5, pp.
751-764
· 0 citations· 61 references
Medicine
TL;DR
Current active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3.
Abstract
The role of immunotherapy in the care of surgical oncology patients promises to expand as investigators and clinicians evaluate new targets and approaches. Currently active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3. Vaccines delivered through mRNA have demonstrated exciting results in early clinical trials and hold promise for expanded application. Investigational approaches include dendritic cell vaccines, peptide vaccines, cytokines therapies, and cellular therapies. These studies have the potential to revolutionize the management of surgical oncology patients and promote durable cures following surgical resection.
Cancer therapeutics has been revolutionized by the introduction of molecularly targeted therapies and immune checkpoint inhibitors (ICIs). The paradigm of neoadjuvant therapy is commonly employed across multiple solid tumors, exhibiting significant clinical benefit as exemplified with ICIs in melanoma and non-small-cel...
D. Nishizaki, R. N. Eskander· Hematology/Oncology Clinics...· 0 citations
Current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines are discussed.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· International Journal of Inn...· 0 citations
Immunotherapy has transformed the management of several extracranial malignancies; however, its efficacy in GBM has been limited. Large clinical trials evaluating immune checkpoint inhibitors have failed to demonstrate meaningful survival benefit in newly diagnosed and recurrent GBM. Other modalities, including dendrit...
Osama Salar, Mehar Masroor, K. Chaudhary et al.· JOURNAL OF PAKISTAN MEDICAL...· 0 citations
This review aims to discuss current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
